It is being studied for obesity, T2D, MASLD, obstructive sleep apnea, and knee osteoarthritis linked to obesity.[4] Eli Lilly began developing retatrutide after the early commercial success of tirzepatide (the dual-agonist molecule that became Mounjaro and Zepbound) signaled that adding more hormone-receptor targets to a single molecule could push weight loss meaningfully higher than what a GLP-1 drug alone could deliver
Another popular option is alpha-lipoic acid (ALA), which acts as both an antioxidant and a helper molecule for other antioxidants like vitamins C and E
Short- and medium-chain fatty acids in energy metabolism: the cellular perspective
Table of Contents 1 Preface 2 Executive Summary 3 Overview of GLP-1 Agonists 4 Patient Profile: GLP-1 Agonists 5 GLP-1 Agonists: Epidemiology Snapshot 6 GLP-1 Agonists: Market Dynamics 7 GLP-1 Agonists: Key Facts Covered 8 GLP-1 Agonists, Drug Pipeline Assessment 9 Drug Pipeline Comparative Analysis 10 GLP-1 Agonists Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs) 11 GLP-1 Agonists Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs) 12 GLP-1 Agonists Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs) 13 GLP-1 Agonists Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs) 14 GLP-1 Agonists, Key Drug Pipeline Companies 15 Regulatory Framework for Drug Approval, By Region 16 Terminated or Suspended Pipeline Products
It could be scalp muscular tension, protruded bone growth, skin tightening, the arrival of DHT to genetically sensitive hair follicles, an inflammatory marker induced by DHT the list goes on
Several launches went the partnership route: Eris Lifesciences with Natco, Ajanta Pharma with Biocon for Asian and African markets
